Biosergen discusses positive results in patients with deadly fungal infections

So far, the majority of patients involved in Biosergen's proof-of-concept study for life-threatening fungal infections have been able to leave the hospital. This suggests...
Oryzon to partner before market entry

Oryzon to partner before market entry

Spanish biopharmaceutical company Oryzon Genomics develops epigenetic personalized medicines for patients with cancer and CNS disorders. BioStock met with CEO Carlos Buesa at this...

Cereno Scientific’s CEO on novel therapies for rare diseases

BioStock met with Cereno Scientifics CEO Sten R. Sörensen at BioEurope. Cereno Scientific is developing novel therapies for rare diseases, with a mission to...
BioStock meets industry experts at BIO-Europe

BioStock meets industry experts at BIO-Europe

The partnering event BIO-Europe has been a vital hub for the life science industry, fostering knowledge exchange and networking for three decades. This year,...
Bent U. Frandsen, CEO of Expres2ion Biotech at BIO-Europe.

ExpreS2ion CEO talking about partnering efforts at BIO-Europe

Heading towards phase I studies with breast cancer vaccine candidate ES2B-C001, ExpreS2ion Biotech is actively looking for partners. Also, having a well-validated platform, the...
Sarah Fredriksson, vd Aqilion

Aqilion’s CEO: “We are driven by dealmaking and scientific data”

With four independent programmes in its pipeline, the Swedish biotech Aqilion is positioned for a series of significant upcoming milestones. CEO Sarah Fredriksson joined...
Sten R. Sörensen, vd Cereno Scientific

The temperature of Cereno Scientific after major news

Cereno Scientific has recently announced the selection of a rare disease, idiopathic pulmonary fibrosis, as the target indication for its second drug candidate, CS014....
Tine Olesen, Biosergen

Biosergen advances BSG005 antifungal drug candidate trial

Biosergen is advancing its drug candidate BSG005, designed as a rescue treatment for patients with invasive fungal infections. The company has enrolled the first...
Chordate

Chordate Medical advances to final phase of exit strategy

Chordate Medical has a clear goal of executing an exit and has now appointed Partner International Switzerland as an advisor to find a buyer...
Sprint Bioscience CEO Johan Emilsson at LSX

Sprint Bioscience CEO comments on deal potential

The LSX Nordic Partnering and Investor Congress is in full swing in Copenhagen, and Sprint Bioscience is one of the attending companies. BioStock met...